Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2011 Oct 15

PMID 21997133

Citations 2

Authors

Blase N Polite

Brooke E Sylvester

Olufunmilayo I Olopade

Affiliations

Soon will be listed here.

Citing Articles

Race, ethnicity, and the diagnosis of breast cancer.

Daly B, Olopade O JAMA. 2015; 313(2):141-2.

PMID: 25585323 PMC: 4504733. DOI: 10.1001/jama.2014.17323.

Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.

Sylvester B, Huo D, Khramtsov A, Zhang J, Smalling R, Olugbile S Clin Cancer Res. 2011; 18(2):350-9.

PMID: 22114137 PMC: 3272273. DOI: 10.1158/1078-0432.CCR-11-1397.

References

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Le Marchand L, Wilkens L, Kolonel L, Henderson B . The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2005; 14(5):1198-203. DOI: 10.1158/1055-9965.EPI-04-0840. View

Watanabe T, Wu T, Catalano P, Ueki T, Satriano R, Haller D . Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001; 344(16):1196-206. PMC: 3584633. DOI: 10.1056/NEJM200104193441603. View

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Van Cutsem E, Kohne C, Lang I, Folprecht G, Nowacki M, Cascinu S . Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29(15):2011-9. DOI: 10.1200/JCO.2010.33.5091. View

Yothers G, Sargent D, Wolmark N, Goldberg R, OConnell M, Benedetti J . Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011; 103(20):1498-506. PMC: 3196480. DOI: 10.1093/jnci/djr310. View

Obeidat N, Pradel F, Zuckerman I, Trovato J, Palumbo F, DeLisle S . Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care. 2010; 16(7):515-22. View

Liang J, Huang K, Cheng Y, Hsu H, Cheng A, Hsu C . P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer. 2002; 97(4):451-7. DOI: 10.1002/ijc.1637. View

10.

Polite B, Sing A, Sargent D, Grothey A, Berlin J, Kozloff M . Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2011; 118(4):1083-90. DOI: 10.1002/cncr.26394. View

11.

Tammemagi C, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D . Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294(14):1765-72. DOI: 10.1001/jama.294.14.1765. View

12.

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

13.

Sanoff H, Sargent D, Green E, McLeod H, Goldberg R . Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009; 27(25):4109-15. PMC: 2734422. DOI: 10.1200/JCO.2009.21.9527. View

14.

Ahnen D, Feigl P, Quan G, Lovato L, Bunn Jr P, Stemmerman G . Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998; 58(6):1149-58. View

15.

David McCollum A, Catalano P, Haller D, Mayer R, Macdonald J, Benson 3rd A . Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94(15):1160-7. DOI: 10.1093/jnci/94.15.1160. View

16.

Hofmann L, Lee S, Waddell B, Davis K . Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum. 2009; 53(1):9-15. DOI: 10.1007/DCR.0b013e3181bdcdb2. View

17.

Edwards B, Ward E, Kohler B, Eheman C, Zauber A, Anderson R . Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2009; 116(3):544-73. PMC: 3619726. DOI: 10.1002/cncr.24760. View

18.

Baldwin L, Dobie S, Billingsley K, Cai Y, Wright G, Dominitz J . Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005; 97(16):1211-20. PMC: 3138542. DOI: 10.1093/jnci/dji241. View

19.

Soneji S, Iyer S, Armstrong K, Asch D . Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health. 2010; 100(10):1912-6. PMC: 2936993. DOI: 10.2105/AJPH.2009.184192. View

20.

Zhu H, Guo W, Zhang L, Davis J, Teraishi F, Wu S . Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther. 2005; 4(3):451-6. DOI: 10.1158/1535-7163.MCT-04-0162. View